Geneva, July 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127188) titled 'A multi-center prospective exploratory study on the treatment of fulminant acne with IL-17a inhibitor vunakizumab injection' on June 26.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: West China Hospital of Sichuan University
Condition:
Acne fulminans
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-07-01
Target Sample Size: Vunakizumab treatment group:32;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=329859
Published by HT Digital Content Services with permission from Health Daily Digest....